MedDataX Logo

Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder

NCT ID: NCT01003405

Last Updated: 2010-07-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the long-term safety, efficacy and pharmacokinetics of KUC-7483 in patients with overactive bladder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase II Study of KUC-7483 in Patients With Overactive Bladder

NCT00742833

Overactive Bladder (OAB)
COMPLETED PHASE2

A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder

NCT01004315

Overactive Bladder
COMPLETED PHASE3

Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

NCT00658684

Overactive Bladder
COMPLETED PHASE3

Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder

NCT00479505

Urinary Bladder, Overactive
COMPLETED PHASE2

A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients

NCT00840645

Urinary Bladder, Overactive
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

KUC-7483

Group Type EXPERIMENTAL

KUC-7483

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KUC-7483

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have successfully completed the Phase III double-blind study.

Exclusion Criteria

* Patients with serious adverse events or clinically significant adverse events in the Phase III double-blind study.
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kissei Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yasuhiro Omori

Role: STUDY_DIRECTOR

Clinical Development Department, Kissei pharmaceutical Co., Ltd.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Japan

Hokkaido,Tohoku,Kanto,Chubu,Kansai,Shikoku,Kyushu, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KUC1302

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
NCT00798434 COMPLETED PHASE4
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
NCT00561951 COMPLETED PHASE2
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
NCT00212706 COMPLETED PHASE2
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
NCT03175029 COMPLETED PHASE2
A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
NCT00231790 COMPLETED PHASE2
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
NCT00212732 COMPLETED PHASE3
A Study of YM178 in Patients With Symptomatic Overactive Bladder
NCT00527033 COMPLETED PHASE2
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01043666 COMPLETED PHASE3
A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder
NCT03566134 COMPLETED PHASE2
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
NCT00170755 COMPLETED PHASE3
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
NCT00966004 COMPLETED PHASE3
PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder
NCT00340704 COMPLETED PHASE2
Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
NCT00730535 COMPLETED PHASE4
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
NCT00290563 COMPLETED PHASE2
Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
NCT00408954 COMPLETED PHASE2
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
NCT01054222 COMPLETED PHASE4
Antibiotic Usage Prior to OnabotulinumtoxinA Injection
NCT04754737 RECRUITING NA
Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
NCT02820844 COMPLETED PHASE3
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
NCT03572231 COMPLETED
Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
NCT00335660 TERMINATED PHASE2
A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)
NCT01099345 TERMINATED
Optimizing Overactive Bladder Treatment
NCT03904407 COMPLETED NA
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
NCT00171184 COMPLETED PHASE4
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
NCT04305743 RECRUITING PHASE4
A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence
NCT00749632 COMPLETED PHASE2